Table 1

Effect of rh-APC on platelet aggregation

Treatment	Platelet Aggregation (% Inhibition)^1-a
Treatment	ADP (10 μM)^1-b	AA (0.65 mM)^1-b	PAF (0.3 μM)	Thrombin (0.1–0.35 U/ml)
Ex vivo
Vehicle (n = 4)	13.7 ± 5.7	4.3 ± 3.0	3.0 ± 1.6	8.0 ± 4.6
rh-APC (mg/kg/h)
0.5 (n = 3)	5.4 ± 5.4	4.2 ± 4.2	1.9 ± 1.9	2.2 ± 2.2
1.0 (n = 3)	8.9 ± 5.0	13.9 ± 0.4	1.4 ± 1.2	2.6 ± 2.6
2.0 (n = 3)	19.5 ± 14.7	30.1 ± 25	0.5 ± 0.5	0.1 ± 0.1
In vitro
rh-APC (μg/ml)
5.0 (n = 4)	13.2 ± 3.1	12.8 ± 1.0	5.0 ± 3.2	2.9 ± 2.9

Each value represents the mean ± S.E. of the number of experiments in parentheses.

↵1-a Each value represents the mean ± S.E. of the percentage of inhibition of platelet aggregation.
↵1-b ADP- and AA-induced platelet aggregation was performed in the presence of a nonaggregating, priming concentration of epinephrine (0.85 μM).